Company Profile: MKT Enterprise

CED Life Science Conference 2017 - Innovation Room

Sub-sector: Medical Device                                                                
Year Founded: 2012

COMPANY PROFILE
Ovarian cancer affects 1 in 74 women in their lifetime, is the 4th deadliest cancer for women and one of the few remaining without a reliable early detection tool. MKT's patent pending device and procedure have been manufactured under FDA design controls with a ISO-13485 registered firm with line of sight to 510(k) approval through a clear predicate. MKT conducted an IRB approved test which successfully collected 18 samples from 5 patients, The reimbursement infrastructure is in place to enable over $5,000 per test, and considering pap smears (an early detection tool for cervical cancer) has 29.4M tests done per year, we believe the market potential to be very large.

FOUNDERS/MANAGEMENT TEAM
David Freed
Tom Mazzoli
Maria Ellis
Kim McDonald
Frank Antonacci

KEY MILESTONES TO DATE

  • Funding: <$1MM
  • Successful testing of product within IRB approved study on 5 patients
  • Collecting 18 samples which showed excellent matching to corresponding pathology from hysterectomy
  • Letter from FDA indicating 510k path as appropriate one
  • Patent filings globally

POWERED BY
Bio Tech Trans, 8 Rivers Capital

CONTACT
David Freed
david@mktenterprise.com
South Windsor, CT

Learn more about the CED Life Science Conference.